S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
A $226B Copper Spending Jackpot (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
A $226B Copper Spending Jackpot (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
A $226B Copper Spending Jackpot (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:RARE

Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News

$36.30
+0.63 (+1.77%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$35.23
$36.80
50-Day Range
$33.72
$43.14
52-Week Range
$33.36
$88.22
Volume
1.51 million shs
Average Volume
742,389 shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$92.86

Ultragenyx Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
155.8% Upside
$92.86 Price Target
Short Interest
Bearish
4.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.82mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$198,579 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.50) to ($6.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

154th out of 1,043 stocks

Pharmaceutical Preparations Industry

55th out of 510 stocks

RARE stock logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock News Headlines

Ultragenyx Announces Departure of Chief Financial Officer
Ultragenyx Pharma Q3 Loss Widens
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx to Participate at Citi BioPharma Conference
A family races the clock
Analyst Ratings for Ultragenyx Pharmaceutical
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Company Calendar

Last Earnings
11/02/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
Employees
1,119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$92.86
High Stock Price Forecast
$142.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+155.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-454,020,000.00
Net Margins
-197.47%
Pretax Margin
-195.38%

Debt

Sales & Book Value

Annual Sales
$351.41 million
Book Value
$6.69 per share

Miscellaneous

Free Float
65,409,000
Market Cap
$2.54 billion
Optionable
Optionable
Beta
1.20

Key Executives

  • Dr. Emil D. Kakkis M.D. (Age 62)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $1.28M
  • Ms. Mardi C. DierMs. Mardi C. Dier (Age 58)
    Exec. VP & CFO
    Comp: $812.24k
  • Mr. John Richard Pinion IIMr. John Richard Pinion II (Age 56)
    Chief Quality Operations Officer & Exec. VP of Translational Sciences
    Comp: $743.58k
  • Dr. Camille L. Bedrosian M.D.Dr. Camille L. Bedrosian M.D. (Age 69)
    Chief Medical Officer & Exec. VP
    Comp: $825.08k
  • Mr. Erik HarrisMr. Erik Harris (Age 52)
    Exec. VP & Chief Commercial Officer
    Comp: $797.57k
  • Mr. Theodore A. HuizengaMr. Theodore A. Huizenga (Age 51)
    Sr. VP, Corp. Controller & Principal Accounting Officer
  • Mr. Dennis Karl HuangMr. Dennis Karl Huang (Age 57)
    Chief Technical Operations Officer & Exec. VP
  • Ms. Danielle Keatley
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Karah Herdman Parschauer J.D.Ms. Karah Herdman Parschauer J.D. (Age 44)
    Chief Legal Officer & Exec. VP
  • Mr. Ernie W. Meyer (Age 58)
    Chief HR Officer & Exec. VP













RARE Stock - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2023?

10 Wall Street analysts have issued 1-year price targets for Ultragenyx Pharmaceutical's shares. Their RARE share price forecasts range from $50.00 to $142.00. On average, they expect the company's share price to reach $92.86 in the next twelve months. This suggests a possible upside of 155.8% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2022?

Ultragenyx Pharmaceutical's stock was trading at $84.09 at the start of the year. Since then, RARE stock has decreased by 56.8% and is now trading at $36.30.
View the best growth stocks for 2022 here
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported ($1.08) EPS for the quarter, topping analysts' consensus estimates of ($1.43) by $0.35. The biopharmaceutical company had revenue of $81.65 million for the quarter, compared to analysts' expectations of $78.16 million. Ultragenyx Pharmaceutical had a negative net margin of 197.47% and a negative trailing twelve-month return on equity of 84.14%. During the same period in the previous year, the firm earned ($1.13) earnings per share.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.79%), Price T Rowe Associates Inc. MD (6.79%), BlackRock Inc. (5.60%), Federated Hermes Inc. (5.44%), State Street Corp (3.65%) and RTW Investments LP (3.37%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $36.30.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $2.54 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($9.74) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

The company employs 1,119 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 12/1/2022 by MarketBeat.com Staff